GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
GH Research：這家歐洲生物技術公司報告了2023年全年財務業績和業務更新
Nasdaq-listed, GH Research (NASDAQ:GHRS) is a clinical-stage biopharma business developing novel 5-MeO-DMT therapies as transformative treatment of psychiatric and neurological disorders.
在納斯達克上市的GH Research（納斯達克股票代碼：GHRS）是一家臨床階段的生物製藥企業，正在開發新的5-meo-DMT療法，作爲精神和神經系統疾病的變革性治療方法。
Its reported yearly financial results show:
其報告的年度財務業績顯示：
Cash position of $ 222.7 million by December 31, 2023, an 11.5% decrease as compared to that held by December 31, 2022.
Yearly R&D expenses totaled $29.8 million, a 45% increase as compared to the $20.5 million spent in 2022.
Yearly G&A expenses totaled $11.4 million, a 12.8% increase as compared to the $10.1 million spent in 2022.
Yearly net loss of $35.6 million (or $0.68 loss per share), a 58% rise from the 2022 net loss ($22.5 million, or $0.43 loss per share.)
截至2023年12月31日，現金狀況爲2.227億美元，與截至2022年12月31日的現金狀況相比下降了11.5％。
每年的研發費用總額爲2980萬美元，與2022年的2,050萬美元相比增長了45％。
每年的併購支出總額爲1140萬美元，與2022年的1,010萬美元相比增長了12.8％。
年度淨虧損3560萬美元（合每股虧損0.68美元），較2022年的淨虧損（2,250萬美元，合每股虧損0.43美元）增長了58％。
Additional financial...
20...
登入免費觀看全文
登入/註冊